Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-26 @ 3:16 PM
NCT ID:
NCT07455032
Brief Summary:
The goal of this clinical trial is to learn if drug CADI-05, when used together with pembrolizumab (an FDA approved immunotherapy), can help treat locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in adults. It will also learn about the safety of drug CADI-05. The main questions it aims to answer are:
* Does using CADI-05 together with pembrolizumab help the immune system fight cancer better and lead to better results for patients?
* What side effects or health problems might happen when people receive these two treatments?
Participants will:
* Get pembrolizumab by IV (through a vein) once on day 1 of week 1 and again day 1 of week 4. This is standard of care treatment.
* Get CADI-05 as a small injection into the skin once a week for 5 weeks. This is the experimental (research) treatment.
* Visit the clinic every week for treatments, checkups and tests for 5 weeks.
* Have surgery between week 6 and week 7.
* Return to the clinic once for a follow-up visit about 30 days after surgery.
Study:
NCT07455032
Study Brief:
Protocol Section:
NCT07455032